Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  GenMark Diagnostics, Inc    GNMK

GENMARK DIAGNOSTICS, INC (GNMK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Glancy Prongay & Murray LLP : Continues Investigation on Behalf of GenMark Diagnostics, Inc. Investors (GNMK)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 07:31pm CEST

Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of GenMark Diagnostics, Inc. (“GenMark” or the “Company”) (NASDAQ: GNMK) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the GenMark investigation page on our website www.glancylaw.com/case/genmark-diagnostics-inc.

On November 2, 2017, GenMark disclosed that the administrative approval process for ePlex in Europe was taking significantly longer than expected—in some cases in excess of 180 days—which was affecting revenue generation.

On this news, GenMark’s share price fell $3.00 or approximately 41%, to close at $4.26 per share on November 3, 2017, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased GenMark securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GENMARK DIAGNOSTICS, INC
07/16GenMark Diagnostics Schedules Second Quarter Financial Results Conference Cal..
GL
07/05GENMARK DIAGNOSTICS : Patent Issued for Capture Ligand Controls, Blocking Probes..
AQ
06/29GENMARK DIAGNOSTICS : Announces FDA Submission of its ePlex Blood Culture Identi..
AQ
06/28GenMark Diagnostics Announces FDA Submission of its ePlex Blood Culture Ident..
GL
06/28GENMARK DIAGNOSTICS : Patent Issued for Capture Ligand Controls, Blocking Probes..
AQ
06/06GenMark Diagnostics to Present at the William Blair 38th Annual Growth Stock ..
GL
05/31GENMARK DIAGNOSTICS, INC. : Submission of Matters to a Vote of Security Holders ..
AQ
05/03GENMARK DIAGNOSTICS : to Present at the Bank of America Merrill Lynch 2018 Healt..
AQ
05/02GenMark Diagnostics to Present at the Bank of America Merrill Lynch 2018 Heal..
GL
05/01GENMARK DIAGNOSTICS : 1Q Earnings Snapshot
AQ
More news
News from SeekingAlpha
07/06GenMark Diagnostics Starting To Deliver, But Consistency Is A Key Issue 
06/29GenMark Diagnostics submits ePlex blood culture identification Gram Positive .. 
05/14WEEK 20 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
05/01GenMark Diagnostics' (GNMK) CEO Hany Massarany on Q1 2018 Results - Earnings .. 
05/01GenMark Diagnostics beats by $0.01, beats on revenue 
Financials ($)
Sales 2018 71,0 M
EBIT 2018 -43,6 M
Net income 2018 -46,3 M
Debt 2018 2,50 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,54x
EV / Sales 2019 4,52x
Capitalization 391 M
Chart GENMARK DIAGNOSTICS, INC
Duration : Period :
GenMark Diagnostics, Inc Technical Analysis Chart | GNMK | US3723091043 | 4-Traders
Technical analysis trends GENMARK DIAGNOSTICS, INC
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 10,2 $
Spread / Average Target 46%
EPS Revisions
Managers
NameTitle
Hany Massarany President, Chief Executive Officer & Director
James Charles Fox Chairman
Brian Mitchell Senior Vice President-Operations
Scott Mendel CFO & Principal Accounting Office
Daryl Jay Faulkner Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
GENMARK DIAGNOSTICS, INC67.39%391
THERMO FISHER SCIENTIFIC9.96%84 971
DANAHER CORPORATION5.76%69 298
INTUITIVE SURGICAL41.96%59 405
BOSTON SCIENTIFIC CORPORATION33.72%46 017
ILLUMINA38.22%45 128